Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Pathogens

    Cell Entry and Receptor Usage for SARS-CoV-2

    By Global Biodefense StaffFebruary 24, 2020
    Share
    Facebook LinkedIn Reddit Email

    The capacity to predict the zoonotic potential of newly detected viruses has been severely hindered by a lack of functional data for these animal virus sequences.

    Here, we have developed a rapid and cost-effective platform with which to functionally test large groups of related viruses for zoonotic potential. We show that host protease processing during viral entry is a significant barrier for several lineage B viruses and that bypassing this barrier allows several lineage B viruses to enter human cells through an unknown receptor.

    We also demonstrate how different lineage B viruses can recombine to gain entry into human cells, and confirm that human ACE2 is the receptor for the recently emerging SARS-CoV-2.

    Taken together with the latest outbreak of SARS-CoV-2 in humans, these findings underscore the importance of continued surveillance of coronaviruses at the sequence and functional levels in order to better prepare for the next emerging virus.

    Letko, M., Marzi, A. & Munster, V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nature Microbiology (2020). https://doi.org/10.1038/s41564-020-0688-y


    This information is not intended as medical advice or clinician guidance. This content contains edited excerpts to bring attention to the work of the researchers and study authors. Please support their efforts and click through for the full context.

    COVID-19 Magazine Edition 11 March 2020 SARS-CoV-2
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleDeploying Smart NanoAgents to Fight Disease
    Next Article Trial Shows Two Drugs Not Better Than One When Treating MRSA

    Related Stories

    COVID Moonshot Consortium Announces Crowd-Sourced Small Molecule Discovery

    November 11, 2023

    WHO Updates Guidance on Treatments for COVID-19

    November 11, 2023

    Novavax’s Prototype COVID-19 Vaccine Nuvaxovid Receives Full Approval in Singapore

    October 18, 2023

    New Method Improves Quantification of Ricin in Complex Matrices

    September 20, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Dec 5
    10:45 am - 3:00 pm EST

    Meeting the Moment: Biodefense Policy, Procurement, and Public Health

    Dec 6
    Virtual Event Virtual Event
    6:00 am - 7:00 am EST

    AMR One Health Priority Research Agenda: Transmission

    Mar 12
    Virtual Event Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.